HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Biliary Tract CancerMelanoma
Interventions
DRUG

HX009+IN10018

"The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily."

Trial Locations (1)

Unknown

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Hanx Biopharmaceuticals, Ltd.

INDUSTRY

NCT06708663 - HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours | Biotech Hunter | Biotech Hunter